Valuation Astellas Pharma Inc. Deutsche Boerse AG

Stocks

YPH

JP3942400007

Pharmaceuticals

Real-time Estimate Tradegate 08:03:41 02/10/2026 BST			5-day change	1st Jan Change
12.65 ^EUR	+1.20%		-5.30%	+12.31%

09-24	Astellas Pharma Inc. Doses First Patient In Phase 3 Study Of Setidegrasib In Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer	CI
09-16	Astellas Pharma Inc. Announces Executive Changes	CI

Company Valuation: Astellas Pharma Inc.

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	3,519,738	3,381,409	2,946,773	2,589,390	4,512,563	4,142,758	-	-
Change	-	-3.93%	-12.85%	-12.13%	74.27%	-8.2%	-	-
Enterprise Value (EV) ¹	3,203,752	3,004,569	2,611,086	3,232,444	4,796,910	4,083,579	3,662,104	3,286,816
Change	-	-6.22%	-13.1%	23.8%	48.4%	-14.87%	-10.32%	-10.25%
P/E	28.5x	34.7x	173x	51x	15.5x	10.8x	11.4x	14.8x
PBR	2.39x	2.24x	1.85x	1.71x	2.47x	1.98x	1.8x	1.71x
PEG	-	-1.8x	-2.1x	0x	0x	0.3x	-2.3x	-0.6x
Capitalization / Revenue	2.72x	2.23x	1.84x	1.35x	2.11x	1.77x	1.89x	2.13x
EV / Revenue	2.47x	1.98x	1.63x	1.69x	2.24x	1.74x	1.67x	1.69x
EV / EBITDA	13.6x	12.6x	14.2x	13.5x	8.31x	5.47x	5.31x	5.62x
EV / EBIT	20.6x	22.6x	102x	78.8x	12.5x	8.19x	7.81x	9.11x
EV / FCF	14.1x	10.3x	-3.88x	20.5x	9.72x	8.83x	6.73x	6.47x
FCF Yield	7.08%	9.7%	-25.8%	4.87%	10.3%	11.3%	14.9%	15.5%
Dividend per Share ²	50	60	70	74	78	80.15	83.08	85.31
Rate of return	2.62%	3.19%	4.26%	5.12%	3.1%	3.47%	3.6%	3.69%
EPS ²	67.08	54.24	9.51	28.35	162.8	213.4	202.8	156.1
Distribution rate	74.5%	111%	736%	261%	47.9%	37.6%	41%	54.7%
Net sales ¹	1,296,163	1,518,619	1,603,672	1,912,323	2,139,245	2,346,509	2,189,300	1,946,328
EBITDA ¹	235,370	238,767	183,358	240,171	577,227	746,611	689,540	584,956
EBIT ¹	155,686	133,029	25,518	41,039	382,633	498,451	469,145	360,750
Net income ¹	124,086	98,714	17,045	50,747	291,535	366,804	345,577	262,363
Net Debt ¹	-315,986	-376,840	-335,687	643,054	284,347	-59,179	-480,654	-855,942
Reference price ²	1,911.00	1,883.00	1,643.50	1,446.50	2,519.00	2,310.50	2,310.50	2,310.50
Nbr of stocks (in thousands)	1,841,831	1,795,756	1,792,986	1,790,107	1,791,411	1,793,014	-	-
Announcement Date	27/04/22	27/04/23	25/04/24	25/04/25	27/04/26	-	-	-

¹JPY in Million²JPY

Estimates

P/E, Detailed evolution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	32.69x	11.85x	24.08x	0.6%	1,025B
JOHNSON & JOHNSON	28.77x	6.4x	17.91x	2.06%	623B
ABBVIE INC.	32.89x	7.71x	15.93x	2.67%	459B
MERCK & CO., INC.	104.62x	5.85x	24.82x	2.37%	355B
ROCHE HOLDING AG	18.99x	4.63x	11.47x	2.87%	336B
NOVARTIS AG	20.13x	5.23x	12.95x	3.06%	270B
ASTRAZENECA PLC	20.27x	4.21x	12x	2.1%	247B
AMGEN INC.	25.72x	6.72x	11.97x	2.48%	220B
GILEAD SCIENCES, INC.	-44.61x	6.5x	25.4x	2.23%	183B
Average	26.61x	6.57x	17.39x	2.27%	413.14B
Weighted average by Cap.	31.73x	7.64x	18.71x	1.95%